Novo Nordisk launches new social responsibility strategy to defeat diabetes

Novo Nordisk declared the start of a new social responsibility strategy: ‘Defeat Diabetes’. The strategy reinforces the commitment of Novo Nordisk and introduces new long-term ambitions to supply access to affordable diabetes care to vulnerable patients in each and every country and to make sure that no child should die due to type 1 diabetes.

Today, one in every 11 people within the world has diabetes, a figure that’s projected to rise to at least one in nine by 2045 if action isn’t taken. Diabetes places a serious burden on health systems, and Novo Nordisk is committed working with health authorities and other partners within the countries where it operates, to stop and treat the disease.

“Our purpose to defeat diabetes is necessary now more than ever as diabetes continues to rise, and at a time when the world is suffering from the most devastating pandemic in recent times,” said Lars Fruergaard Jørgensen, CEO of Novo Nordisk.

“In addition to innovative medicine, we are committed to help societies defeat diabetes by accelerating prevention to halt the rise of the disease and providing access to affordable care to vulnerable patients in every country. Vulnerability has many faces, and diabetes hits the hardest in vulnerable communities. I am proud that we are stepping up our efforts and working in partnerships to tackle the diabetes crisis at a time of profound need.”

As a primary step in our ambition to supply access to affordable insulin to vulnerable patients in every country, Novo Nordisk is decreasing the ceiling price of human insulin from 4 US Dollars to 3 US Dollars per vial in 76 low- and middle-income countries, which are a part of the company’s existing Access to Insulin Commitment. This is applicable to Least Developed Countries as defined by the UN, other low-income countries as defined by the World Bank and middle-income countries where large low-income populations lack enough health coverage.

To support the aspiration of the company that no child should die from type 1 diabetes, Novo Nordisk is expanding its Changing Diabetes in Children programme to reach 100,000 children by 2030, up from 25,000. The programme provides care and life-saving medicine for youngsters with type 1 diabetes in low-resource settings.

Novo Nordisk

Vice-President of the International Diabetes Federation and partner of the Changing Diabetes in Children initiative Dr Naby Balde states the urgency of action: “Diabetes is rising in every part of the world and good health is not an equal opportunity. The lives of thousands of children living with type 1 diabetes in vulnerable communities have been saved by the Changing Diabetes in Children initiative. I welcome Novo Nordisk’s efforts to vastly expand its reach and their broader efforts to defeat diabetes.”

This article has been posted by a News Hour Correspondent. For queries, please contact through [email protected]
No Comments